ClinicalTrials.gg

Program

Capecitabine

Also written as “capecitabine”, “capecitabine [Xeloda]” and “Utidelone in combination with capecitabine”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Neoplasms, led by 13 companies.

Furthest: phase 4, since Jul 12, 200472 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche430 open or runningphase 4since Jul 12, 2004May 2, 2000none ahead
Sanofi90 open or runningphase 3since Apr 20, 2004Apr 20, 2004none ahead
R-Pharm60 open or runningphase 3since Mar 26, 2004Nov 12, 2002none ahead
Novartis41 open or runningphase 3since Jul 26, 2007Jul 26, 2007Apr 14, 2027phase 2 · NCT06247995
Qilu Pharmaceutical21 open or runningphase 2since Jun 1, 2024Feb 10, 2018none ahead
academy-military-medical-science-china10 open or runningphase 2since Jul 14, 2008Jul 14, 2008none ahead
bio-cancer-treatment-international-limited10 open or runningphase 2since Mar 14, 2014Mar 14, 2014none ahead
ebg-medaustron-gmbh11 open or runningno phasesince May 10, 2021May 10, 2021Dec 31, 2026NCT04894643
iOMEDICO10 open or runningphase 4since Aug 28, 2014Aug 28, 2014none ahead
NovoCure10 open or runningno phasesince Feb 20, 2020Feb 20, 2020none ahead
pharmatech-oncology10 open or runningphase 2since Nov 9, 2001Nov 9, 2001none ahead
Pierre Fabre10 open or runningphase 2since Oct 3, 2016Oct 3, 2016none ahead
prologue-research-international10 open or runningphase 3since Jun 5, 2003Jun 5, 2003none ahead

Also a collaborator on its studies: Exelixis, clovis-oncology-inc, Johnson & Johnson, parexel, baili-bio-chengdu-pharmaceutical-co-ltd, Zai Lab, chengdu-biostar-pharmaceuticals, Regeneron Pharmaceuticals, GlaxoSmithKline and yakult-honsha-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Jul 12, 2004.

  1. Nov 17, 2014Phase 2 study in NeoplasmsNovartis · NCT02294786 · 62 enrolled · Czechia, Israel, Poland and more
  2. Sep 24, 20152 phase 3 studies in Stomach NeoplasmsHoffmann-La Roche · NCT02560974, NCT02563054
  3. Sep 30, 2015Phase 2 study in Pancreatic NeoplasmsHoffmann-La Roche · NCT02565641 · 63 enrolled · Korea, Republic of
  4. Oct 1, 20152 phase 4 studies in Colorectal NeoplasmsHoffmann-La Roche · NCT02567331, NCT02581423
  5. Oct 14, 2015Phase 2 study in Carcinoma, HepatocellularHoffmann-La Roche · NCT02576964 · 16 enrolled · China, Taiwan, Thailand
  6. Nov 16, 2015Phase 2 study in Nasopharyngeal NeoplasmsHoffmann-La Roche · NCT02608073 · 45 enrolled · Hong Kong, Indonesia, Malaysia and more
  7. Feb 25, 2016Phase 2 study in Rectal NeoplasmsHoffmann-La Roche · NCT02694718 · 60 enrolled · Switzerland
  8. Jul 25, 2016Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02846428 · 182 enrolled · France
  9. Oct 3, 2016Pierre Fabre's first study: phase 2 study in Breast NeoplasmsNew to Pierre FabrePierre Fabre · NCT03887130 · 152 enrolled
  10. Feb 10, 2018Qilu Pharmaceutical's first study: phase 1 study in Colonic NeoplasmsNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT03435666 · 45 enrolled
  11. Feb 20, 2020NovoCure's first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
  12. May 10, 2021ebg-medaustron-gmbh's first study: no phase study in Pancreatic NeoplasmsNew to ebg-medaustron-gmbhebg-medaustron-gmbh · NCT04894643 · 10 planned · Austria
  13. Jan 17, 2024Phase 2 study in Breast NeoplasmsNovartis · NCT06247995 · 20 enrolled · United States, Australia, Canada and more
  14. Jun 1, 2024Phase 2 study in Advanced Solid TumorQilu Pharmaceutical · NCT06446388 · 360 planned · China

Ahead

  1. Dec 31, 2026Primary completion: no phase study in Pancreatic Neoplasmsebg-medaustron-gmbh · NCT04894643
  2. Apr 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNovartis · NCT06247995

TargetBeta

TYMS →read by rule
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
FluorouracilruleSanofiphase 482
TegafurruleOtsukaphase 325

Studies

The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06446388Advanced Solid Tumor · China2Not yet recruitingQilu PharmaceuticalJun 30, 2026360
NCT06247995Breast Neoplasms · United States, Australia, Canada and more2Active, not recruitingNovartisApr 14, 202720
NCT04894643Pancreatic Neoplasms · Austria–Recruitingebg-medaustron-gmbhDec 31, 202610
NCT04281576Stomach Neoplasms · Hong Kong–CompletedNovoCureJun 7, 202428
NCT03435666Colonic Neoplasms1UNKNOWNQilu PharmaceuticalOct 201845
NCT03887130Breast Neoplasms2CompletedPierre FabreApr 18, 2013152
NCT02846428Breast Neoplasms · France2CompletedHoffmann-La RocheDec 2011182
NCT02694718Rectal Neoplasms · Switzerland2CompletedHoffmann-La RocheAug 200660
NCT02608073Nasopharyngeal Neoplasms · Hong Kong, Indonesia, Malaysia and more2CompletedHoffmann-La RocheNov 200945
NCT02581423Colorectal Neoplasms · Bulgaria4CompletedHoffmann-La RocheMar 200763
NCT02576964Carcinoma, Hepatocellular · China, Taiwan, Thailand2CompletedHoffmann-La RocheNov 200816
NCT02567331Colorectal Neoplasms · Bulgaria4CompletedHoffmann-La RocheApr 200628
NCT02565641Pancreatic Neoplasms · Korea, Republic of2CompletedHoffmann-La RocheSep 200663
NCT02563054Stomach Neoplasms · Argentina, Belize, Brazil and more3CompletedHoffmann-La RocheAug 2010316
NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan3CompletedHoffmann-La RocheNov 20121,035
NCT02294786Neoplasms · Czechia, Israel, Poland and more2TerminatedNovartisOct 19, 201762
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedHoffmann-La RocheMay 31, 20191,044
NCT02248571Breast Neoplasms · Germany4CompletediOMEDICOAug 31, 201785
NCT02089633Carcinoma, Hepatocellular · Hong Kong2Completedbio-cancer-treatment-international-limitedSep 201617
NCT02085005Colorectal Cancer Metastatic2WithdrawnSanofiAug 20160
NCT02013830Liver Neoplasms · Australia, Hong Kong, Singapore and more2CompletedHoffmann-La RocheMar 200845
NCT01955629Colorectal Cancer Metastatic · Italy2TerminatedSanofiMar 20154
NCT01783444Breast Neoplasms · United States, Argentina, Australia and more2CompletedNovartisJul 2, 2018309
NCT01748773Stomach Neoplasms · Turkey2CompletedHoffmann-La RocheAug 21, 201534
NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more3TerminatedHoffmann-La RocheFeb 2015296
NCT01290718Breast Neoplasms · Taiwan2TerminatedHoffmann-La RocheDec 20124
NCT01245582Carcinoma, Hepatocellular3WithdrawnSanofiFeb 20140
NCT01227707Colorectal Neoplasms · Italy2CompletedHoffmann-La RocheAug 201043
NCT01135498Colorectal Neoplasms · Spain2CompletedHoffmann-La RocheApr 201090
NCT01130337Stomach Neoplasms · Spain2CompletedHoffmann-La RocheJun 201436
NCT01118377Brainstem Glioma · United States2CompletedHoffmann-La RocheJan 201345
NCT01077739Colorectal Neoplasms · Belgium2CompletedHoffmann-La RocheJan 201275
NCT01077726Breast Neoplasms · France2CompletedHoffmann-La RocheDec 20103
NCT00977379Breast Neoplasms · France2TerminatedHoffmann-La RocheFeb 201124
NCT00929240Breast Neoplasms · Brazil, China, Egypt and more3CompletedHoffmann-La RocheJun 2014287
NCT00925769Pancreatic Neoplasms · Austria1CompletedHoffmann-La RocheDec 201332
NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more2CompletedHoffmann-La RocheFeb 18, 201333
NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more2CompletedHoffmann-La RocheDec 201588
NCT00796718Colorectal Neoplasms · Slovakia2CompletedHoffmann-La RocheAug 201062
NCT00717951Advanced Breast Cancer2UNKNOWNacademy-military-medical-science-chinaDec 2009120
NCT00634088Breast Neoplasms · United States, Australia, Italy1TerminatedR-PharmJun 201013
NCT00623805Colorectal Neoplasms · Turkey3CompletedHoffmann-La RocheMay 2012123
NCT00577031Colorectal Neoplasms · Italy4CompletedHoffmann-La RocheAug 2011205
NCT00576901Breast Neoplasms · Spain2TerminatedHoffmann-La RocheJun 200923
NCT00568022Breast Neoplasms · Japan1CompletedR-PharmJan 20109
NCT00532948Glioma · United States1CompletedHoffmann-La RocheOct 201024
NCT00508274Breast Neoplasms · China, Hong Kong3TerminatedNovartisDec 2, 201552
NCT00502671Colorectal Neoplasms · Russian Federation4CompletedHoffmann-La RocheMar 2012228
NCT00448136Neoplasms · France2CompletedHoffmann-La RocheNov 201183
NCT00421824Rectal Neoplasms · Spain2CompletedSanofiNov 2010108
NCT00411229Stomach Neoplasms · China, Korea, Republic of, Taiwan3CompletedSanofiNov 20121,035
NCT00382720Stomach Neoplasms · United States, Belgium, France and more2CompletedSanofiApr 2010275
NCT00345761Colorectal Neoplasms · Japan2CompletedHoffmann-La RocheOct 200864
NCT00263029Rectal Neoplasms2CompletedSanofiMar 200718
NCT00207129Neoplasms · United States1CompletedR-PharmDec 200525
NCT00174616Rectal Neoplasms · Belgium, France, Germany and more2CompletedSanofiNov 200787
NCT00121836Breast Neoplasms · United States4CompletedHoffmann-La RocheDec 2008109
NCT00118755Colorectal Neoplasms2CompletedHoffmann-La RocheApr 2009435
NCT00112918Colorectal Neoplasms · United States3CompletedHoffmann-La RocheJun 20103,451
NCT00087620Breast Neoplasms · United States4TerminatedHoffmann-La RocheOct 2004

How it is read

Names in the registry

  • “Capecitabine”, 62 entries
  • “capecitabine”, 16 entries
  • “capecitabine [Xeloda]”, 12 entries
  • “Utidelone in combination with capecitabine”, 3 entries
  • “Capecitabine [Xeloda]”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Capecitabine (Hoffmann-La Roche): development program | ClinicalTrials.gg